Financial “hocus pocus” and the (potential) effectiveness of Prostvac VF

If readers come across a report this week suggesting that Barvarian Nordic’s Prostvac VF is likely to fail in the demonstration of effectiveness in its ongoing Phase III trial, you might want to treat that report with some caution. … READ MORE …